

September 1, 2022



SCYNEXIS to Present Posters Highlighting Ibrexafungerp Data at Four Upcoming Scientific Meetings in September 2022

JERSEY CITY, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: [SCYX](#)), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will present posters at four upcoming U.S. and international medical conferences in September.

United States

- [**Mycoses Study Group Education and Research Consortium \(MSGERC\) Biennial Meeting**](#) – September 7-9, 2022, Albuquerque, N.M.

Title: Outcomes of Oral Ibrexafungerp in Refractory Patients with *Candida* Infections from an Open-Label Study in Patients with Serious Fungal Infections (FURI)

Date: Friday, September 9

Time: 3:30 pm – 5:00 pm MDT

Presenter: Nkechi Azie, M.D.

Title: Outcomes of Oral Ibrexafungerp in the Treatment of 10 Patients with *Candida auris* Infections, from the CARES Study

Date: Friday, September 9

Time: 3:30 pm – 5:00 pm MDT

Presenter: Nkechi Azie, M.D.

- [**World Anti-Microbial Resistance \(AMR\) Congress**](#) – September 7-9, 2022, National Harbor, Md.

Title: Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of CDC Urgent Threat Pathogen, *Candida auris*

Date: Wednesday, September 7, and Thursday, September 8

Time: 10:20 am EDT both days

Presenter: Thomas King, MS, MPH

International

- [**International Immunocompromised Host Society \(ICHS\)**](#) – September 8-11, 2022, Basel, Switzerland

Title: Oral Ibrexafungerp Outcomes in Patients with Chronic Mucocutaneous Candidiasis (CMC)

Date: Saturday, September 10

Time: 10:00 am -10:30 am CEST

Presenters: Riina Rautemma-Richardson and Chris Eades, Manchester University

- [21st Congress of the International Society for Human and Animal Mycology \(ISHAM\)](#) –September 20-24, 2022, New Delhi, India

Title: All-Cause Mortality in Patients with Invasive Candidiasis or Candidemia from an Interim Analysis of a Phase 3 Open-label Study (FURI)

Date: Wednesday, September 21

Time: 12:30 pm - 1:30 pm IST

Presenter: Juergen Prattes, M.D., Medical University of Graz

Title: Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI)

Date: Wednesday, September 21

Time: 12:30 pm - 1:30 pm IST

Presenter: Juergen Prattes, M.D., Medical University of Graz

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS scientists are developing the company's lead asset, ibrexafungerp (formerly known as SCY-078), as a broad-spectrum, systemic antifungal for multiple fungal indications in both the community and hospital settings. SCYNEXIS has initiated the launch of its first commercial product in the U.S., [BREXAFEMME® \(ibrexafungerp tablets\)](#). The U.S. Food and Drug Administration (FDA) approved BREXAFEMME on June 1, 2021. The FDA has accepted the Company's sNDA submission for prevention of recurrent vulvovaginal candidiasis (RVVC) and assigned a PDUFA decision date of November 30, 2022. In addition, late-stage clinical investigation of oral ibrexafungerp for the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing. For more information, visit www.scynexis.com.

CONTACT:

Investors

Irina Koffler

LifeSci Advisors, LLC

ikoffler@lifesciadvisors.com

Media

Debbie Etchison

SCYNEXIS

debbie.etchison@scynexis.com



Source: Scynexis